Here's Why Nektar Therapeutics Is Skyrocketing 70% in November

Here's Why Nektar Therapeutics Is Skyrocketing 70% in November

After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics (NASDAQ: NKTR) shares shot higher. However, that wasn't the only good news it's released so far this month. Management also unveiled impressive early-stage trial data for NKTR-214, a wholly owned immuno-oncology drug that's being studied for use alongside Bristol-Myers Squibb's (NYSE: BMY) multibillion-dollar drug Opdivo. Can Nektar Therapeutics' stock continue to climb?

In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to explain what's next for Nektar Therapeutics and its investors. Also, they discuss why Loxo Oncology's (NASDAQ: LOXO) game-changing deal with Bayer AG (NASDAQOTH: BAYRY) disappointed investors and how the FDA approval of a new smart pill could change medicine forever.

A full transcript follows the video.

Continue reading

Source: Fool.com